ESC Professional Premium Access

CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Congress Presentation

About the speaker

Professor Michael Holinstat

University of Michigan, Ann Arbor (United States of America)
0 follower

6 more presentations in this session

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Speaker: Doctor G. Abelian (US)


Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Speaker: Associate Professor B. Rocca (Rome, IT)


Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis

Speaker: Doctor T. Attachaipanich (Chiang Mai, TH)


Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

Speaker: Doctor K. Matli (Beirut, LB)


Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.

Speaker: Doctor F. Santoro (Foggia, IT)


Access the full session

Challenges and advances in antithrombotic therapy

Speakers: Professor M. Holinstat, Doctor G. Abelian, Associate Professor B. Rocca, Doctor T. Attachaipanich, Doctor K. Matli...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb